Buscar
Mostrando ítems 1-5 de 5
Cost-effectiveness analysis of second-line pharmacological treatment of acromegaly in Spain
(Taylor&Francis, 2020-05-06)
[Abstract]
Objective: To estimate the cost-effectiveness of second-line pharmacological treatments in patients
with acromegaly resistant to first-generation somatostatin analogues (FG SSA) from the Spanish
National ...
Cost-effectiveness analysis of preoperative treatment of acromegaly with somatostatin analogue on surgical outcome
(Elsevier, 2015-08-20)
[Abstract] Context. There is no uniform standard of care for acromegaly. Due to the high costs involved, steps must be taken to ensure the cost-effective delivery of treatment.
Objective. Taking the results of an earlier ...
Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly
(Springer, 2020-07-28)
[Abstract]
Purpose. Recent data indicate that extended dosing intervals (EDIs) with lanreotide autogel 120 mg are effective and well-received among patients with acromegaly who have achieved biochemical control with monthly ...
Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: the ACROCOMB study
(Elsevier, 2016-11-04)
[Abstract] PURPOSE: To describe real-world use of lanreotide combination therapy for acromegaly.
PATIENTS AND METHODS: ACROCOMB is a retrospective observational Spanish study of patients with active acromegaly treated ...
Mortality in acromegaly diagnosed in older individuals in Spain is higher in women compared to the general spanish population
(Oxford Academic, 2023-03-14)
[Abstract] Context: There are no data on mortality of acromegaly diagnosed in older individuals.
Objective: This work aimed to compare clinical characteristics, growth hormone-related comorbidities, therapeutic approaches, ...